Acrivon Therapeutics: A Precision Oncology Play Gaining Insider Momentum

Acrivon Therapeutics, Inc. (ACRV:US) is a clinical-stage biopharmaceutical company pioneering precision medicines for cancer treatment. Founded in 2018, the company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match drugs to patients most likely to respond, focusing on hard-to-treat tumors like endometrial, ovarian, and bladder cancers. By analyzing drug effects on the entire signaling network of tumor cells, Acrivon aims to improve response rates and accelerate development. As of January 19, 2026, the company's market capitalization stands at approximately $62.5 million, reflecting its early-stage status but also potential upside in a volatile biotech sector.

Recent Insider Purchases Signal Confidence

In mid-January 2026, Acrivon saw a cluster of open-market insider purchases, signaling executive confidence in the company’s outlook.

• On January 14, CEO and Co-Founder Peter Blume-Jensen bought 49,000 shares at an average price of $1.68, investing about $82,320.

• Also on January 14, CFO Adam Levy purchased 8,832 shares at $1.70 per share, totaling roughly $15,014.

• Prior to that, on January 13, COO Eric Devroe acquired 10,000 shares at $1.72, a $17,200 purchase, lifting his total holdings to 75,308 shares.

The buys were made while the stock was trading near its 52-week low, pointing to insiders viewing the valuation as an attractive entry point.

Why This Cluster Stands Out

What amplifies the credibility of these buys is the pedigrees of the insiders involved. Peter Blume-Jensen, MD, PhD, is Acrivon's Founder, President, and CEO, with decades of experience in oncology research and drug development. He invented the AP3 platform and has held leadership roles at major firms like Merck, Daiichi Sankyo, and Serono, where he advanced multiple oncology programs into the clinic. 

Adam Levy, PhD, MBA, Acrivon's CFO and Senior VP of Investor Relations and Corporate Affairs, brings a unique blend of scientific and financial expertise. With a PhD in Molecular Biology and an MBA from Northwestern's Kellogg School, Levy has over 25 years in biotech, including roles at Zentalis Pharmaceuticals where he managed investor relations. His dual background positions him to evaluate both the scientific promise and market viability of Acrivon's pipeline, making his substantial stake increase especially telling. 

Together, these executives' actions suggest they see undervalued growth ahead, backed by their intimate knowledge of the company's operations.

Solid Financial Footing and Promising Clinical Milestones Fuel Bullish Outlook

Financially, Acrivon remains well-positioned for a pre-revenue biotech. As of September 30, 2025 (the latest reported quarter), the company held $134.4 million in cash, cash equivalents, and marketable securities, providing a runway into the second quarter of 2027. 

The real catalyst for optimism lies in recent clinical progress, announced on January 8, 2026. Interim data from the ongoing Phase 2b trial of lead candidate ACR-368 (a CHK1/2 inhibitor) in OncoSignature-positive endometrial cancer patients showed a 39% overall response rate (ORR), climbing to 44% in those with two or fewer prior therapies, a meaningful improvement over standard treatments. To accelerate development, Acrivon is expanding the trial into the EU.

Beyond ACR-368, early Phase 1 data for ACR-2316 (a dual WEE1/PKMYT1 inhibitor) was shared, marking steady pipeline advancement. 

In a biotech landscape where precision medicine is key, Acrivon's AP3-driven approach, combined with insider buying, financial stability, and clinical momentum, paints a compelling picture for long-term investors. While risks like trial setbacks remain, these developments could position ACRV as a standout in oncology innovation.